Several studies reported that a broad number of t-MN cases, ranging from 20% to 60%, exhibited somatic mutations in well-known genes associated with CHIP, including DNMT3A, TET2, ASXL1, TP53 and PPM1D [37,38,39,40,41]. Here, TP53 is linked to therapy-related myeloid neoplasm.